Pacira proposes $250M convertible note offering due 2029; up to $50M share repurchase

Pacira BioSciences, Inc.

Proposed offering of $250M aggregate principal of Convertible Senior Notes due 2029, with initial purchasers' option for additional $37.5M.
Proceeds to repurchase portion of outstanding 0.750% 2025 Notes, fund capped call transactions, and repurchase up to $50M of common stock.
Capped call transactions expected to reduce dilution upon conversion and offset cash payments in excess of principal amount.
Entered First Amendment to Credit Agreement to permit $150M share repurchase program and the proposed note offering.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Pacira BioSciences, Inc. amended First TLA Amendment with JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders (effective 2024-05-08).

Action: amendment
Agreement: credit facility
Counterparty: JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders
Effective: 2024-05-08

Exact text from the filing

On May 8, 2024, Pacira BioSciences, Inc. (the “Company”), JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders entered into a first amendment (the “First TLA Amendment”) to the Credit Agreement, dated as of March 31, 2023

View on SEC.gov

308 material agreements filed in the last 30 days. Browse all material agreements →

Pacira BioSciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-058675

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.